Antiretroviral therapy and central nervous system HIV type 1 infection

Journal of Infectious Diseases

Volumn 197, Issue SUPPL. 3, 2008, Pages

  Price, Richard W ^a,b   Spudich, Serena ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BIOLOGICAL MARKER; CORTICOSTEROID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANTIVIRAL RESISTANCE; BLOOD CYTOLOGY; BRAIN DYSFUNCTION; BRAIN INJURY; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; CLINICAL TRIAL; CONVALESCENCE; DEMENTIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHORIC DREAM; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INCIDENCE; INFECTION CONTROL; INFLAMMATION; JC VIRUS; MENTAL DISEASE; MOLECULAR DYNAMICS; MONOTHERAPY; MYOPATHY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PERFORMANCE MEASUREMENT SYSTEM; PERIPHERAL NERVOUS SYSTEM TOXICITY; PHARMACEUTICAL CARE; PLEOCYTOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUANTITATIVE DIAGNOSIS; REVIEW; SKELELETAL MUSCLE TOXICITY; SYMPTOMATOLOGY; TOXIC MYOPATHY; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNPLEASANT DREAM; VIRAL GENETICS; VIREMIA;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; HIV-1; HUMANS;

EID: 44149084718     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/533419     Document Type: Review

References (130)

1. Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42:1736-9.
2. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001; 15:837-45.
3. Ritola K, Pilcher CD, Fiscus SA, et al. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol 2004; 78:11208-18.
4. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42:679-88.
5. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.
6. Navia BA, Jordan BD, Price RW. The AIDS dementia complex. I. Clinical features. Ann Neurol 1986; 19:517-24.
7. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex. II. Neuropathology. Ann Neurol 1986; 19:525-35.
8. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239:586-92.
9. Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 1994; 36:673-6 (erratum: Ann Neurol 1995; 37:140).
10. Brew B, Rosenblum M, Cronin K, Price R. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995; 38:563-70.
11. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 1996; 39:705-11.
12. Navia B, Price RW. An overview of the clinical and biological features of the AIDS dementia complex. In: Gendelman HE, Grant I, Everall I, Lipton SA, Swindells S, eds. The neurology of AIDS. 2nd ed. Oxford: Oxford University Press, 2005:339-56.
13. Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 14:403-18.
14. Price RW. Neurological complications of HIV infection. Lancet 1996; 348:445-52.
15. Price RW. Neurologic disease. In: Dolin R, Masur H, Saag MS, eds. AIDS therapy. 2nd ed. New York: Churchill Livingstone, 2003: 737-57.
16. Robertson K, Kopnisky K, Mielke J, et al. Assessment of neuroAIDS in Africa. J Neurovirol 2005; 11(Suppl 1):7-16.
17. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55:320-8.
18. Price RW, Staprans S. Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol 1997; 42:675-8.
19. Price RW. The two faces of HIV infection of cerebrospinal fluid. Trends Microbiol 2000; 8:387-91.
20. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993; 33:343-9.
21. Sidtis JJ, Dafni U, Slasor P, et al. Stable neurological function in subjects treated with 2′3′-dideoxyinosine. J Neurovirol 1997; 3: 233-40.
22. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trials Group and Neurological AIDS Research Consortium Study Team. AIDS 1999; 13:1677-85.
23. Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003; 60:1388-90.
24. Brew BJ, Halman M, Catalan J, et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials 2007; 2:e13.
25. Sidtis JJ. Evaluation of the AIDS dementia complex in adults. Res Publ Assoc Res Nerv Ment Dis 1994; 72:273-87.
26. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) - a marker of active HIV-related neurodegeneration. J Neurol 2007; 254:1026-32.
27. Gisslén M, Hagberg L, Rosengren L, et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2007; 2:112-9.
28. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17:1897-906.
29. Vazeux R, Brousse N, Jarry A, et al. AIDS subacute encephalitis: identification of HIV-infected cells. Am J Pathol 1987; 126:403-10.
30. Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 1992; 66:285-91.
31. Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006; 20:879-87.
32. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33-44.
33. Kim WK, Avarez X, Williams K. The role of monocytes and perivascular macrophages in HIV and SIV neuropathogenesis: information from non-human primate models. Neurotox Res 2005; 8:107-15.
34. Aquaro S, Ronga L, Pollicita M, Antinori A, Ranazzi A, Perno CF. Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: role of cells of monocytemacrophage lineage. J Neurovirol 2005; 11(Suppl 3):58-66.
35. Li W, Galey D, Mattson MP, Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res 2005; 8:119-34.
36. Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 2006; 4:307-18.
37. Jones GJ, Barsby NL, Cohen EA, et al. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 2007; 27: 3703-11.
38. Buscemi L, Ramonet D, Geiger JD. Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-α-mediated neurotoxicity. Neurobiol Dis 2007; 26:661-70.
39. Price RW, Sidtis JJ. Evaluation of the AIDS dementia complex in clinical trials. J Acquir Immune Defic Syndr 1990; 3(Suppl 2): S51-60.
40. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a working group of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:778-85.
41. Price RW. Management of AIDS dementia complex and HIV-1 infection of the nervous system. AIDS 1995; 9(Suppl A):S221-36.
42. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-99.
43. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158:1079-83.
44. Navia BA, Gonzalez RG. Functional imaging of the AIDS dementia complex and the metabolic pathology of the HIV-1 infected brain. Neuroimaging Clinics of North America 1997; 7:431-45.
45. Boska MD, Mosley RL, Nawab M, et al. Advances in neuroimaging for HIV-1 associated neurological dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring. Curr HIV Res 2004; 2:61-78.
46. Tucker K, Robertson K, Lin W, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004; 157: 153-62.
47. Avison MJ, Nath A, Berger JR. Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci 2002; 25:468-73.
48. Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005; 2:197-214.
49. Price RW, Epstein LG, Becker JT, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology 2007; 69:1781-8.
50. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid β42 and tau levels correlate with AIDS dementia complex. Neurology 2005; 65:1490-2.
51. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslén M. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 2007; 69:1536-41.
52. Gisslén M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007; 195:1774-8.
53. Cinque P, Vago L, Mengozzi M, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998; 12:1327-32.
54. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002; 16: 2145-9.
55. Monteiro de Almeida S, Letendre S, Zimmerman J, Lazzaretto D, McCutchan A, Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 2005; 169:144-52.
56. Andersson LM, Hagberg L, Rosengren L, Fuchs D, Blennow K, Gisslén M. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia-case report. BMC Infect Dis 2006; 6:141.
57. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686-96.
58. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689-98.
59. Marra CM, Maxwell CL, Collier AC, Robertson KR, Imrie A. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7:37.
60. Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 2005; 79: 7959-66.
61. Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005; 79:10830-4.
62. Harrington PR, Connell MJ, Meeker RB, Johnson PR, Swanstrom R. Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection. J Infect Dis 2007; 196:1058-67.
63. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997; 71:2059-71.
64. Strain MC, Letendre S, Pillai SK, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005; 79:1772-88.
65. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000; 14: 1949-54.
66. Lanier ER, Sturge G, McClernon D, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with abacavir. AIDS 2001; 15: 747-51.
67. Di Stefano M, Sabri F, Leitner T, et al. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol 1995; 33:352-5.
68. Stingele K, Haas J, Zimmermann T, et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 2001; 56:355-61.
69. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
70. Letendre S, Capparelli EV, Best B, et al. Better antiretroviral penetration into the central nervous system is associated with lower CSF viral load [abstract 741]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006. Available at: http://www.retroconference.org/AbstractSearch/ Default.aspx?Confp17.
71. Letendre S, Ances B, Gibson S, Ellis RJ. Neurologic complications of HIV disease and their treatment. Top HIV Med 2007; 15:32-9.
72. Bestetti A, Presi S, Pierotti C, et al. Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol 2004; 10(Suppl 1):52-7.
73. Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 2005; 191:890-8.
74. Power C, McArthur JC, Johnson RT, et al. Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol 1995; 202:89-104.
75. Power C, Zhang K, van Marle G. Comparative neurovirulence in lentiviral infections: the roles of viral molecular diversity and select proteases. J Neurovirol 2004; 10(Suppl 1):113-7.
76. Thomas ER, Dunfee RL, Stanton J, et al. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 2007; 360:105-19.
77. Gisslén M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21:271-6.
78. Price RW, Paxinos EE, Grant RM, et al. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 2001; 15:1251-9.
79. Price RW, Deeks SG. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: clinical and pathogenetic implications for the central nervous system. J Neurovirol 2004; 10(Suppl 1):44-51.
80. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 1993; 168:1285-8.
81. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 1992; 6: 461-5.
82. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991; 29:202-9.
83. Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferon-γ-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 2005; 168:154-63.
84. Cinque P, Brew BJ, Gisslén M, Hagberg L, Price RW. Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. In: Berger J, Portegies P, eds. Handbook of clinical neurology: AIDS and HIV dementias. Amsterdam: Elsevier, 2006:261-300.
85. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990; 28:556-60.
86. Gisslén M, Hagberg L, Cinque P, Brew B, Price R. CSF markers in the management of CNS HIV infection and the AIDS dementia complex. In: Goodkin K, Shapshak P, Vrma A, eds. The spectrum of neuro-AIDS disorders: pathophysiology, diagnosis, and treatment. Washington, DC: American Society for Microbiology (in press).
87. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004; 157:3-10.
88. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18(Suppl 1):S75-8.
89. Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 2006; 19:358-61.
90. Polis MA, Suzman DL, Yoder CP, et al. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS 2003; 17:1167-72.
91. Mellgren A, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005; 10:701-7.
92. Yilmaz A, Svennerholm B, Hagberg L, Gisslén M. Cerebrospinal fluid viral loads reach less than 2 copies/mL in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther 2006; 11: 833-7.
93. Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999; 13:1051-61.
94. Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54:927-36.
95. McArthur JC, Letendre SL. Is the glass three-quarters full or one-quarter empty? J Infect Dis 2006; 194:1628-31.
96. Perno C-F, Newcomb FM, Davis DA, et al. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 1998; 178:413-22.
97. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 2007; 4:42-7.
98. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:544-52.
99. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:168-73.
100. Lipton SA. Treating AIDS dementia. Science 1997; 276:1629-30.
101. Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998; 51:221-8.
102. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000; 54: 233-5.
103. Zink MC, Uhrlaub J, Dewitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293:2003-11.
104. Turchan J, Sacktor N, Wojna V, Conant K, Nath A. Neuroprotective therapy for HIV dementia. Curr HIV Res 2003; 1:373-83.
105. Berger AR, Arezzo JC, Schaumburg HH, et al. 2′,3′- dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993; 43:358-62.
106. Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006; 66:867-73.
107. Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005; 32:247-60.
108. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001; 81:1537-44.
109. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9:849-63.
110. Cornblath DR, Hoke A. Recent advances in HIV neuropathy. Curr Opin Neurol 2006; 19:446-50.
111. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006; 29:865-74.
112. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006; 7:544-8.
113. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-21.
114. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41: 1648-53.
115. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
116. Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir Ther 2006; 11:263-5.
117. Robertson K, Su Z, Krambrink A, et al. This is your brain off drugs: neurocognitive function before and after ART discontinuation in patients with high CD4 nadir (ACTG A5170) [abstract 113]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007. Available at: http:// www.retroconference.org/AbstractSearch/Default.aspx? Confp17.
118. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005; 11(Suppl 3):16-22.
119. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006; 67:383-8.
120. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60:162-73.
121. Berger JR, Mucke L. Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1988; 38:1060-5.
122. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9(Suppl 1):47-53.
123. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047-52.
124. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9(Suppl 1):73-80.
125. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9(Suppl 1):25-31.
126. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047-52.
127. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9(Suppl 1):73-80.
128. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9(Suppl 1):25-31.
129. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9(Suppl 1):88-92.
130. Pazzi A, Galli L, Costenaro P, et al. The relationship between outcome of progressive multifocal leukoencephalopathy and type and response to ART in previously HAART-untreated patients [abstract 380]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007. Available at: http://www.retroconference.org/AbstractSearch/Default.aspx? Confp17.